sunday tribune logo
 
go button spacer This Issue spacer spacer Archive spacer

In This Issue title image
spacer
News   spacer
spacer
spacer
Sport   spacer
spacer
spacer
Business   spacer
spacer
spacer
Property   spacer
spacer
spacer
Tribune Review   spacer
spacer
spacer
Tribune Magazine   spacer
spacer

 

spacer
Tribune Archive
spacer

Market Monkey



NEW highs last week, both for the markets and for Market Monkey's account balance.

We'll start with the trivia . . . more all-time highs for the Dow. Now to more important matters.

I finally closed out my Yahoo! position. The stock was strong on Wednesday and I covered at $24.50. To be honest, the argument for staying short here still looks strong to me but my position was a small one and, despite the profits it afforded me over the last month, I had grown bored with it.

I'm still bearish on Yahoo!

and will take a decent-sized short if it gets up to the $25.50 area, where there is a lot of congestion on the chart. For those thinking of doing the same, around $27 looks like a good place to place a stop.

Still holding IBM. This is a pretty boring stock to hold, but it's looking good for further gains. Its progress last week has been slow but steady and continued 52-week highs look likely to me. I'm up nearly 500 here and, with my stop loss order at breakeven, I can sit back and relax with this one.

My best profits came, yet again, from Elan. As I pointed out last week, the stock has been trading in a predictable $15.20-$16.20 range for the past month or so. The previous week saw me go short at $15.90 but the stock didn't quite make it to my $15.30 target. By Monday morning, it had risen past my original entry and was threatening to hit my stop ($16.30). Any trader will tell you never to double down on a losing position.

It's wise advice but I decided to make an exception here and I doubled my initial short at $16.10. Why? I couldn't resist. Quite simply, I was pretty sure Elan wouldn't hit that level.

I was right . . . beautifully so. The stock hit a high of $16.15 before heading southwards, helped on its way by a Goodbody analyst cutting his full-year forecast for Tysabri . . . Elan's muchhyped MS drug . . . from $78m to $25m. As the closing bell neared, Elan had slipped all the way down to $15.40. I gleefully closed out the entire position for an overall gain of almost 1,000 (that's after commissions, as I not-sohumbly point out).

Should I have held out for my original target of $15.30 (which was hit the next day)? I don't think so.

Earnings were due to be




Back To Top >>


spacer

 

         
spacer
contact icon Contact
spacer spacer
home icon Home
spacer spacer
search icon Search


advertisment




 

   
  Contact Us spacer Terms & Conditions spacer Copyright Notice spacer 2007 Archive spacer 2006 Archive